Our research focuses on understanding and controlling the cellular and molecular events that lead to transplant rejection, with the aim of improving long-term outcomes for transplant recipients.

Imaging immune cells after transplanation © TRIG image
Imaging immune cells after transplanation

Our group is a dynamic, multi-disciplinary international team of around 18 scientists and clinician scientists. We are dedicated to translating our research from the lab into the clinic by finding new ways to diagnose and treat patients, with the aim of optimising patient care, and prolonging the life of a donated organ.

With this in mind, we are investigating how to :

  1. increase the selectivity of immunosuppression such that only the destructive responses the immune system makes against the transplant are suppressed
  2. predict the when rejection is going to happen more reliably to enable anti-rejection treatment to be started before the transplant has actually been damaged by the immune response

Advances in each of these areas would allow immunosuppressive drug therapy to be tailored to the specific needs of the individual transplant recipient. In other words, the development of personalised or precision medicine for each individual transplant patient.

Our work is supported with substantial funding from Kidney Research UK,  the Medical Research Council, and the European Union. We also receive funding from RESTORE (Burn and Wound Research), OHSRC (Oxfordshire Health Research Services Committee), the Academy of Medical Sciences, and the University of Oxford Medical Research Fund - we are grateful to all our funders for allowing us to continue with our research.

Our team

Related research themes